Robert Chafin Vice President, Industry Research and Engagement Bluegrass Business Media
In 2020, several major drug makers announced their intention to no longer provide discounts to providers under Medicare’s 340B Drug Discount Program. Litigation against HHS and HRSA on their enforcement of 340B drug pricing laws is currently pending and not expected to be resolved quickly. With a new administration, what changes will be implemented regarding enforcement? What is the immediate impact of the litigation? What changes could be on the horizon? This session will discuss what you can expect both in the short-term and long-term.
Learning Objectives:
1. Discuss the manufacturer’s claims and updates on pending litigation.
2. Identify any changes that could result from pending litigation and Biden administration.
3. Evaluate both short-term and long-term impacts on your organization.
Session Material: